TMF Completeness vs TMF Quality: What an Audit Should Actually Test

TMF completeness asks whether expected essential records exist; TMF quality asks whether the right records accurately and contemporaneously document what happened. Both are necessary, but they detect different inspection-readiness risks.

Reviewed by: BioBoston CRO Editorial Team

TMF Completeness vs TMF Quality: What an Audit Should Actually Test: evidence, sponsor decision and action matrix with five controls.

TMF completeness asks whether expected essential records exist; TMF quality asks whether the right records accurately and contemporaneously document what happened. Both are necessary, but they detect different inspection-readiness risks.

Who should use this: Clinical Quality, TMF, Clinical Operations, or sponsor oversight leader responsible for inspection-ready trial documentation. Decision trigger: TMF completeness, quality, timeliness, or inspection readiness is uncertain.

Decision factors and what they mean

Begin with the most consequential control and the evidence needed to resolve it. The following matrix connects each decision to records and an accountable action, rather than treating the list as a generic compliance checkbox.

Control / question Evidence to examine Sponsor action
Expected vs present Trial-specific inventory and accountable owner Identify missing or legitimately inapplicable items
Timeliness Date of event, approval and filing Distinguish delayed filing from missing creation
Accuracy Correct study, site, version, signatures and content Test whether records represent actual activity
Context Linked decisions, deviations, correspondence and oversight Reconstruct reasons behind material actions
Access Audit trail, permissions, archive export and retrieval Ensure essential records are usable by sponsor and regulators

For teams that need support implementing this across functions, BioBoston CRO TMF Audits can help adapt the controls to the study, vendors, and decision calendar.

Working through the controls

1. Expected vs present

Evidence: Trial-specific inventory and accountable owner. Decision: Identify missing or legitimately inapplicable items. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.

2. Timeliness

Evidence: Date of event, approval and filing. Decision: Distinguish delayed filing from missing creation. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.

3. Accuracy

Evidence: Correct study, site, version, signatures and content. Decision: Test whether records represent actual activity. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.

4. Context

Evidence: Linked decisions, deviations, correspondence and oversight. Decision: Reconstruct reasons behind material actions. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.

5. Access

Evidence: Audit trail, permissions, archive export and retrieval. Decision: Ensure essential records are usable by sponsor and regulators. Record the responsible function and the approved source version, and keep any remaining exceptions visible to the sponsor before this item is closed.

Red flags that should change the plan

  • Assuming 100% completeness means audit-ready.
  • Double-counting duplicates.
  • Excluding vendor-controlled records from quality review.

Decision gate and governance

Report completeness and quality scores separately with criticality-weighted exceptions and remediation owners. The control owner should record the decision, evidence version, date, residual uncertainty and next re-review trigger. Where delegated providers perform the work, the sponsor should retain the relevant oversight and acceptance evidence.

Regulatory note: Applicable regulations, trial commitments and agreements must be distinguished from nonbinding FDA and ICH guidance. Apply this framework to the actual product, jurisdiction and study.

Need practical support?

Use BioBoston CRO TMF Audits to review the evidence, define decision rights, and build a study-specific action plan for the next milestone.

Related Resources

START A CONVERSATION

Tell Us What Support You Need

Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.


Please do not submit confidential, patient-identifiable, or proprietary information through this form.